

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Baichwal et al.

Serial No. 09/758,003

Filed: January 9, 2001

For: *RIP: Novel Human Protein Involved in  
Tumor Necrosis Factor Signal Transduction*

Group Art Unit: 1645

Examiner: Andres, Janet

Attorney Docket No. T95-006-2

## CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted by fax to  
the Assist Comm for Patents at (703) 872-9306 on March 12, 2003

Signed

Richard Osman

**OFFICIAL****FAX RECEIVED****MAR 13 2003****GROUP 1600**

## RESPONSE TO SPECIES ELECTION REQUIREMENT


The Commissioner for Patents  
Washington, DC 20231

Dear Commissioner:

Thank you for the species election requirement dated Mar 7, 2003.

We elect for initial examination in this application the species identified as "Sequences encoding  $\alpha\Delta 14$  of SEQ ID NO:2". As shown in Table 1 (p.3), this species encodes residues 423-671 of SEQ ID NO:2. This sequence is recited in claim 23.

Note that all the recited RIP polynucleotide truncations are of the same generic RIP-encoding polynucleotide or the same specific RIP-encoding cDNA. The encoded RIP truncations are those issued in priority US Pat No.6,211,337. Accordingly, these deletion mutant species are properly examined together.

Respectfully submitted,  
SCIENCE & TECHNOLOGY LAW GROUP  
Richard Aron Osman, Ph.D., Reg. No. 36,627  
Tel: (650) 343-4341; Fax: (650) 343-4342

"To Help Our Customers Get Patents"  
Mission Statement, USPTO External Customer Services Guide